dehydroepiandrosterone has been researched along with Schizophrenia in 51 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dehydroepiandrosterone (DHEA) augmentation has been reported, in a preliminary fashion, to be useful in the management of schizophrenia symptoms and side effects." | 9.12 | Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. ( Gibel, A; Ratner, Y; Ritsner, MS; Strous, RD; Tsinovoy, G, 2006) |
| " The aim of this study was to investigate for the first time efficacy of DHEA augmentation with standardized antipsychotic medication (olanzapine) and to explore effects of DHEA augmentation on side-effect profiles including weight gain, glucose tolerance, aggression, quality of life and neurocognitive function." | 9.12 | Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. ( Eisner, D; Gal, G; Katz, E; Maayan, R; Strous, RD; Stryjer, R; Viglin, D; Weizman, A, 2007) |
| "Dehydroepiandrosterone (DHEA) or their sulfate conjugate (DHEAS) (together abbreviated DHEA(S)) exert multiple effects in the central nervous system, and may be involved in the pathophysiological processes in schizophrenia." | 9.11 | Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia. ( Biadsy, H; Gibel, A; Maayan, R; Modai, I; Ram, E; Ratner, Y; Ritsner, M; Weizman, A, 2005) |
| "Recent investigation in schizophrenia indicated dehydroepiandrosterone (DHEA) levels to be inversely correlated with extrapyramidal symptomatology (EPS)." | 9.11 | Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial. ( Abramovitch, Y; Assael-Amir, M; Ebert, T; Kotler, M; Maayan, R; Nachshoni, T; Strous, RD; Weizman, A, 2005) |
| "To examine the effects of dehydroepiandrosterone (DHEA) on animal models of schizophrenia." | 7.80 | Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice. ( Kilic, FS; Kulluk, D; Musmul, A, 2014) |
| "Contradictory and confusing reports on serum dehydroepiandrosterone (DHEA) levels in schizophrenia led us to compare the serum concentration of its precursor, pregnenolone (PREG), between medicated schizophrenia patients and healthy subjects." | 7.74 | Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects. ( Gibel, A; Maayan, R; Ritsner, M; Weizman, A, 2007) |
| "The data show that schizophrenia is associated with abnormal levels of cortisol, DHEA-S, NO and AM." | 5.34 | Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. ( Akyol, O; Celik, A; Cicek, HK; Herken, H; Yilmaz, N; Yürekli, M, 2007) |
| "Dehydroepiandrosterone has been recently recognized as neuroactive steroid with several vital neurophysiological activities on membrane receptors, such as N-methyl-d-aspartate, and gamma-aminobutyric acid receptors and on genomic androgen receptors." | 5.33 | Plasma dehydroepiandrosterone levels are strongly increased in schizophrenia. ( Bonaviri, G; Caltagirone, C; di Michele, F; Romeo, E; Spalletta, G, 2005) |
| " No significant association was found between these ratios and severity of psychopathology, and type or dosage of antipsychotic agents." | 5.32 | Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. ( Gibel, A; Maayan, R; Modai, I; Ritsner, M; Strous, RD; Weizman, A, 2004) |
| "Dehydroepiandrosterone (DHEA) is a major circulating neurosteroid in humans and its administration has demonstrated efficacy in the improvement of mood, with increased energy, interest, confidence and activity levels." | 5.32 | Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology. ( Goredetsky, L; Kotler, M; Lapidus, R; Maayan, R; Strous, RD; Weizman, A; Zeldich, E, 2004) |
| " To understand the influence of hormones on schizophrenia symptoms, serum steroids (estradiol, progesterone, follicular stimulating hormone (FSH), luteinising hormone (LH), and dehydroepiandrosterone (DHEA)) and psychopathology (The positive-and-negative-syndrome-scale(PANSS)) and depression (Montgomery-Asberg-Depression-Rating Scale(MADRS)) were collected across 12-weeks in 45 women (mean age 46) diagnosed with schizophrenia." | 5.30 | Dissecting the syndrome of schizophrenia: Associations between symptomatology and hormone levels in women with schizophrenia. ( Gavrilidis, E; Gurvich, C; Hudaib, AR; Kulkarni, J; Thomas, N, 2019) |
| "Lower levels of 7α-hydroxydehydroepiandrosterone, abundant especially in brain, determined for the first time in schizophrenia patients, are in agreement with recent opinion of their neuroprotective and immunoprotective role." | 5.15 | Neuro- and immunomodulatory steroids and other biochemical markers in drug-naive schizophrenia patients and the effect of treatment with atypical antipsychotics. ( Bicikova, M; Hampl, R; Hill, M; Mohr, P; Putz, Z; Ripova, D, 2011) |
| "Data regarding cognitive function, symptom severity, daily doses, side effects of antipsychotic agents and blood levels of DHEA, DHEAS, androstenedione and cortisol were collected among 55 schizophrenia patients in a double-blind, randomized, placebo-controlled, crossover trial with DHEA at three intervals: upon study entry, after 6weeks of DHEA administration (200mg/d), and after 6weeks of a placebo period." | 5.14 | Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA. ( Ritsner, MS; Strous, RD, 2010) |
| "Dehydroepiandrosterone (DHEA) augmentation has been reported, in a preliminary fashion, to be useful in the management of schizophrenia symptoms and side effects." | 5.12 | Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. ( Gibel, A; Ratner, Y; Ritsner, MS; Strous, RD; Tsinovoy, G, 2006) |
| " The aim of this study was to investigate for the first time efficacy of DHEA augmentation with standardized antipsychotic medication (olanzapine) and to explore effects of DHEA augmentation on side-effect profiles including weight gain, glucose tolerance, aggression, quality of life and neurocognitive function." | 5.12 | Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. ( Eisner, D; Gal, G; Katz, E; Maayan, R; Strous, RD; Stryjer, R; Viglin, D; Weizman, A, 2007) |
| "Dehydroepiandrosterone (DHEA) or their sulfate conjugate (DHEAS) (together abbreviated DHEA(S)) exert multiple effects in the central nervous system, and may be involved in the pathophysiological processes in schizophrenia." | 5.11 | Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia. ( Biadsy, H; Gibel, A; Maayan, R; Modai, I; Ram, E; Ratner, Y; Ritsner, M; Weizman, A, 2005) |
| "Recent investigation in schizophrenia indicated dehydroepiandrosterone (DHEA) levels to be inversely correlated with extrapyramidal symptomatology (EPS)." | 5.11 | Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial. ( Abramovitch, Y; Assael-Amir, M; Ebert, T; Kotler, M; Maayan, R; Nachshoni, T; Strous, RD; Weizman, A, 2005) |
| "Neuroactive steroids, including testosterone, dehydroepiandrosterone (DHEA) and its sulfate (DHEA-S) might play an important role in the pathophysiology of schizophrenia." | 4.98 | Testosterone, DHEA and DHEA-S in patients with schizophrenia: A systematic review and meta-analysis. ( Frydecka, D; Kasznia, J; Loska, O; Misiak, B; Moustafa, AA; Samochowiec, J; Stańczykiewicz, B, 2018) |
| "The study showed that pregnenolone was significantly decreased in the parietal cortex in the combined group of patients with schizophrenia or bipolar disorder who died by suicide (n = 13) compared with patients with these disorders who died of other causes (n = 17, p = ." | 3.81 | Exploratory investigation of biomarker candidates for suicide in schizophrenia and bipolar disorder. ( Allen, TB; Bradford, DW; Brancu, M; Brunca, M; Hamer, RM; Kilts, JD; Marx, CE; Naylor, JC; Shampine, LJ; Strauss, JL; Szabo, ST; Youssef, NA, 2015) |
| "To examine the effects of dehydroepiandrosterone (DHEA) on animal models of schizophrenia." | 3.80 | Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice. ( Kilic, FS; Kulluk, D; Musmul, A, 2014) |
| "Alterations in cortisol and dehydroepiandrosterone sulfate (DHEA-S) levels are thought to play a role in the pathophysiology of neuropsychiatric disorders, including schizophrenia." | 3.77 | Serum cortisol and dehydroepiandrosterone-sulfate levels in schizophrenic patients and their first-degree relatives. ( Dogan, O; Kilicli, F; Semiz, M; Yıldırım, O, 2011) |
| "In previous studies we have demonstrated high serum molar ratios of cortisol to dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS) [together abbreviated DHEA(S)], and the value of both cortisol/DHEA(S) molar ratios for prediction of responsivity to antipsychotic treatment in schizophrenia patients." | 3.74 | State and trait related predictors of serum cortisol to DHEA(S) molar ratios and hormone concentrations in schizophrenia patients. ( Gibel, A; Maayan, R; Modai, I; Ram, E; Ratner, Y; Ritsner, M; Weizman, A, 2007) |
| "Contradictory and confusing reports on serum dehydroepiandrosterone (DHEA) levels in schizophrenia led us to compare the serum concentration of its precursor, pregnenolone (PREG), between medicated schizophrenia patients and healthy subjects." | 3.74 | Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects. ( Gibel, A; Maayan, R; Ritsner, M; Weizman, A, 2007) |
| "Forty-five DSM-IV-TR chronic schizophrenia patients were sampled for plasma levels of three steroids: cortisol, dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulphate (DHEA-S)." | 3.74 | Circulatory neurosteroid levels in smoking and non-smoking chronic schizophrenia patients. ( Dannon, P; Iancu, I; Kotler, M; Maayan, R; Poreh, A; Strous, RD; Tchernihovsky, E; Weizman, A, 2007) |
| "The goals of this study were to determine whether alterations in serum dehydroepiandrosterone (DHEA), its sulfated conjugate (DHEAS), androstenedione, testosterone, and progesterone concentrations occur in schizophrenia patients compared with healthy controls over two months, and their associations with psychopathology, emotional distress, and antipsychotic treatment." | 3.73 | Alterations in DHEA metabolism in schizophrenia: two-month case-control study. ( Gibel, A; Maayan, R; Ram, E; Ritsner, M; Weizman, A, 2006) |
| "The data show that schizophrenia is associated with abnormal levels of cortisol, DHEA-S, NO and AM." | 1.34 | Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. ( Akyol, O; Celik, A; Cicek, HK; Herken, H; Yilmaz, N; Yürekli, M, 2007) |
| "Dehydroepiandrosterone has been recently recognized as neuroactive steroid with several vital neurophysiological activities on membrane receptors, such as N-methyl-d-aspartate, and gamma-aminobutyric acid receptors and on genomic androgen receptors." | 1.33 | Plasma dehydroepiandrosterone levels are strongly increased in schizophrenia. ( Bonaviri, G; Caltagirone, C; di Michele, F; Romeo, E; Spalletta, G, 2005) |
| " No significant association was found between these ratios and severity of psychopathology, and type or dosage of antipsychotic agents." | 1.32 | Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. ( Gibel, A; Maayan, R; Modai, I; Ritsner, M; Strous, RD; Weizman, A, 2004) |
| "Dehydroepiandrosterone (DHEA) is a major circulating neurosteroid in humans and its administration has demonstrated efficacy in the improvement of mood, with increased energy, interest, confidence and activity levels." | 1.32 | Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology. ( Goredetsky, L; Kotler, M; Lapidus, R; Maayan, R; Strous, RD; Weizman, A; Zeldich, E, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (11.76) | 18.7374 |
| 1990's | 1 (1.96) | 18.2507 |
| 2000's | 25 (49.02) | 29.6817 |
| 2010's | 18 (35.29) | 24.3611 |
| 2020's | 1 (1.96) | 2.80 |
| Authors | Studies |
|---|---|
| Thomas, N | 1 |
| Gurvich, C | 2 |
| Hudaib, AR | 1 |
| Gavrilidis, E | 1 |
| Kulkarni, J | 2 |
| Ji, E | 1 |
| Weickert, CS | 1 |
| Purves-Tyson, T | 1 |
| White, C | 1 |
| Handelsman, DJ | 1 |
| Desai, R | 1 |
| O'Donnell, M | 1 |
| Liu, D | 1 |
| Galletly, C | 1 |
| Lenroot, R | 1 |
| Weickert, TW | 1 |
| Huang, YC | 1 |
| Hung, CF | 1 |
| Lin, PY | 1 |
| Lee, Y | 1 |
| Wu, CC | 1 |
| Hsu, ST | 1 |
| Chen, CC | 1 |
| Chong, MY | 1 |
| Lin, CH | 1 |
| Wang, LJ | 1 |
| Misiak, B | 1 |
| Frydecka, D | 1 |
| Loska, O | 1 |
| Moustafa, AA | 1 |
| Samochowiec, J | 1 |
| Kasznia, J | 1 |
| Stańczykiewicz, B | 1 |
| Cai, H | 1 |
| Zhou, X | 1 |
| Dougherty, GG | 1 |
| Reddy, RD | 1 |
| Haas, GL | 1 |
| Montrose, DM | 1 |
| Keshavan, M | 1 |
| Yao, JK | 1 |
| Flegr, J | 1 |
| Príplatova, L | 1 |
| Hampl, R | 2 |
| Bicikovíá, M | 1 |
| Ripova, D | 2 |
| Mohr, P | 2 |
| Kilic, FS | 1 |
| Kulluk, D | 1 |
| Musmul, A | 1 |
| Vuksan-Ćusa, B | 2 |
| Sagud, M | 2 |
| Mihaljević-Peleš, A | 1 |
| Jakšić, N | 1 |
| Jakovljević, M | 1 |
| Peixoto, C | 1 |
| Devicari Cheda, JN | 1 |
| Nardi, AE | 1 |
| Veras, AB | 1 |
| Cardoso, A | 1 |
| Youssef, NA | 1 |
| Bradford, DW | 1 |
| Kilts, JD | 1 |
| Szabo, ST | 1 |
| Naylor, JC | 1 |
| Allen, TB | 1 |
| Strauss, JL | 1 |
| Hamer, RM | 1 |
| Brancu, M | 1 |
| Brunca, M | 1 |
| Shampine, LJ | 1 |
| Marx, CE | 1 |
| Magalhães, PV | 1 |
| Dean, O | 1 |
| Andreazza, AC | 1 |
| Berk, M | 1 |
| Kapczinski, F | 1 |
| Radoš, I | 1 |
| Strous, RD | 12 |
| Gibel, A | 8 |
| Maayan, R | 15 |
| Weizman, A | 15 |
| Ritsner, MS | 5 |
| Maninger, N | 1 |
| Wolkowitz, OM | 2 |
| Reus, VI | 2 |
| Epel, ES | 1 |
| Mellon, SH | 1 |
| Kaminsky, M | 1 |
| Blumensohn, R | 1 |
| Spivak, B | 1 |
| Shleifer, T | 1 |
| Boguslavsky, I | 1 |
| Zayed, A | 1 |
| Lerner, V | 1 |
| de Castella, A | 1 |
| Headey, B | 1 |
| Marston, N | 1 |
| Sinclair, K | 1 |
| Lee, S | 1 |
| Fitzgerald, PB | 1 |
| Burger, H | 1 |
| Bicikova, M | 1 |
| Hill, M | 1 |
| Putz, Z | 1 |
| Yıldırım, O | 1 |
| Dogan, O | 1 |
| Semiz, M | 1 |
| Kilicli, F | 1 |
| Ram, E | 4 |
| Biton, D | 1 |
| Cohen, H | 1 |
| Baharav, E | 1 |
| Shirayama, Y | 1 |
| Hashimoto, K | 1 |
| Suzuki, Y | 1 |
| Higuchi, T | 1 |
| Lapidus, R | 2 |
| Stryjer, R | 2 |
| Lustig, M | 1 |
| Kotler, M | 4 |
| Harris, DS | 1 |
| MINSKER, EI | 1 |
| STRAUSS, EB | 1 |
| SANDS, DE | 1 |
| ROBINSON, AM | 1 |
| TINDALL, WJ | 1 |
| STEVENSON, WA | 1 |
| Ritsner, M | 5 |
| Modai, I | 3 |
| Goredetsky, L | 1 |
| Zeldich, E | 1 |
| Goyal, RO | 1 |
| Sagar, R | 1 |
| Ammini, AC | 1 |
| Khurana, ML | 1 |
| Alias, AG | 1 |
| di Michele, F | 1 |
| Caltagirone, C | 1 |
| Bonaviri, G | 1 |
| Romeo, E | 1 |
| Spalletta, G | 1 |
| Ratner, Y | 3 |
| Biadsy, H | 1 |
| Nachshoni, T | 1 |
| Ebert, T | 1 |
| Abramovitch, Y | 1 |
| Assael-Amir, M | 1 |
| Reid, KS | 1 |
| Watson, S | 2 |
| Tsinovoy, G | 1 |
| Gal, G | 1 |
| Viglin, D | 1 |
| Katz, E | 1 |
| Eisner, D | 1 |
| Gallagher, P | 1 |
| Smith, MS | 1 |
| Young, AH | 1 |
| Ferrier, IN | 1 |
| Yilmaz, N | 1 |
| Herken, H | 1 |
| Cicek, HK | 1 |
| Celik, A | 1 |
| Yürekli, M | 1 |
| Akyol, O | 1 |
| Iancu, I | 1 |
| Tchernihovsky, E | 1 |
| Poreh, A | 1 |
| Dannon, P | 1 |
| Elias, A | 1 |
| Kumar, A | 1 |
| Erb, JL | 2 |
| Kadane, JB | 1 |
| Tourney, G | 4 |
| Mickelsen, R | 1 |
| Trader, D | 1 |
| Szabo, R | 1 |
| Davis, V | 1 |
| Oades, RD | 1 |
| Schepker, R | 1 |
| Cyr, M | 1 |
| Calon, F | 1 |
| Morissette, M | 1 |
| Grandbois, M | 1 |
| Di Paolo, T | 1 |
| Callier, S | 1 |
| Yagorowski, Y | 1 |
| Grupper, D | 1 |
| Weiss, M | 1 |
| Shtaif, B | 1 |
| Kaoud, MA | 1 |
| Hatfield, L | 1 |
| Hatfield, LM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Selective Estrogen Receptor Modulators (SERMs) - A Potential New Treatment for Women of Child-bearing Age With Psychotic Symptoms of Schizophrenia[NCT02354001] | Phase 4 | 80 participants (Anticipated) | Interventional | 2011-04-30 | Completed | ||
| Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia?[NCT00361543] | Phase 4 | 54 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Addition of Both Pregnenolone and L-theanine to Ongoing Antipsychotic Treatment for Schizophrenia and Schizoaffective Disorders: an 8-week, Randomized, Double-blind, Placebo-controlled Multicenter Study[NCT01831986] | 60 participants (Anticipated) | Interventional | 2011-01-31 | Enrolling by invitation | |||
| Efficacy and Safety of Pregnenolone Augmentation in the Management of Schizophrenia Patients: a Randomised Double-Blind Placebo-Controlled Trial[NCT00174889] | Phase 1 | 60 participants | Interventional | 2005-01-31 | Completed | ||
| A Randomised Controlled Trial of Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?[NCT01481883] | Phase 4 | 13 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia: an 8-week, Randomized, Double-blind, Placebo-controlled Trial[NCT00847600] | Phase 4 | 60 participants (Anticipated) | Interventional | 2009-03-31 | Completed | ||
| Early Mental Response to Hormonal Treatment in Transgender Men - The EMRE Study[NCT05649605] | 70 participants (Anticipated) | Interventional | 2023-03-07 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for dehydroepiandrosterone and Schizophrenia
| Article | Year |
|---|---|
Testosterone, DHEA and DHEA-S in patients with schizophrenia: A systematic review and meta-analysis.
Topics: Adult; Antipsychotic Agents; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Humans; | 2018 |
The effects of dehydroepiandrosterone (DHEA) in the treatment of depression and depressive symptoms in other psychiatric and medical illnesses: a systematic review.
Topics: Adrenal Insufficiency; Anorexia Nervosa; Antidepressive Agents; Databases, Bibliographic; Dehydroepi | 2014 |
Antioxidant treatments for schizophrenia.
Topics: Acetylcysteine; Allopurinol; Antioxidants; Antipsychotic Agents; Ascorbic Acid; Dehydroepiandrostero | 2016 |
The role of dehydroepiandrosterone (DHEA) in schizophrenia.
Topics: Dehydroepiandrosterone; Humans; Neurotransmitter Agents; Schizophrenia | 2016 |
Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS).
Topics: Adult; Aged; Aging; Animals; Antioxidants; Brain; Dehydroepiandrosterone; Dehydroepiandrosterone Sul | 2009 |
Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials.
Topics: Adjuvants, Immunologic; Animals; Antipsychotic Agents; Central Nervous System; Clinical Trials as To | 2010 |
Dehydroepiandrosterone (DHEA) augmentation in the management of schizophrenia symptomatology.
Topics: Clinical Trials as Topic; Dehydroepiandrosterone; Disease Management; Humans; Schizophrenia | 2005 |
Testosterone for schizophrenia.
Topics: Antipsychotic Agents; Chemotherapy, Adjuvant; Dehydroepiandrosterone; Humans; Randomized Controlled | 2007 |
Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS.
Topics: Alzheimer Disease; Animals; Brain; Dehydroepiandrosterone; Depression; Estrogens; Female; Humans; Ma | 2000 |
12 trials available for dehydroepiandrosterone and Schizophrenia
| Article | Year |
|---|---|
Dissecting the syndrome of schizophrenia: Associations between symptomatology and hormone levels in women with schizophrenia.
Topics: Adult; Biomarkers; Dehydroepiandrosterone; Estradiol; Female; Follicle Stimulating Hormone; Humans; | 2019 |
Dissecting the syndrome of schizophrenia: Associations between symptomatology and hormone levels in women with schizophrenia.
Topics: Adult; Biomarkers; Dehydroepiandrosterone; Estradiol; Female; Follicle Stimulating Hormone; Humans; | 2019 |
Dissecting the syndrome of schizophrenia: Associations between symptomatology and hormone levels in women with schizophrenia.
Topics: Adult; Biomarkers; Dehydroepiandrosterone; Estradiol; Female; Follicle Stimulating Hormone; Humans; | 2019 |
Dissecting the syndrome of schizophrenia: Associations between symptomatology and hormone levels in women with schizophrenia.
Topics: Adult; Biomarkers; Dehydroepiandrosterone; Estradiol; Female; Follicle Stimulating Hormone; Humans; | 2019 |
Hormonal response to dehydroepiandrosterone administration in schizophrenia: findings from a randomized, double-blind, placebo-controlled, crossover study.
Topics: Adrenal Cortex Hormones; Adult; Antipsychotic Agents; Cross-Over Studies; Dehydroepiandrosterone; Do | 2008 |
Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA.
Topics: Adult; Androstenedione; Cognition Disorders; Cross-Over Studies; Dehydroepiandrosterone; Dehydroepia | 2010 |
Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention; Dehydroepiandrosterone; Dose-Response Relationsh | 2010 |
Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention; Dehydroepiandrosterone; Dose-Response Relationsh | 2010 |
Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention; Dehydroepiandrosterone; Dose-Response Relationsh | 2010 |
Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention; Dehydroepiandrosterone; Dose-Response Relationsh | 2010 |
Estrogens and men with schizophrenia: is there a case for adjunctive therapy?
Topics: Adult; Antipsychotic Agents; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Double-Blind | 2011 |
Neuro- and immunomodulatory steroids and other biochemical markers in drug-naive schizophrenia patients and the effect of treatment with atypical antipsychotics.
Topics: Adult; Antibodies; Antipsychotic Agents; Biomarkers; Case-Control Studies; Dehydroepiandrosterone; F | 2011 |
Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia.
Topics: Adult; Antipsychotic Agents; Anxiety Disorders; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfa | 2003 |
Negative correlation between negative symptoms of schizophrenia and testosterone levels.
Topics: Adult; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estradiol; Hair; Humans; Hydrocortiso | 2004 |
Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dehydroepiandrosterone; Drug Resistance; Female; | 2005 |
Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dehydroepiandrosterone; Double-Blind Method; Fema | 2005 |
Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Topics: Adult; Antipsychotic Agents; Attention; Cross-Over Studies; Dehydroepiandrosterone; Double-Blind Met | 2006 |
Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cognition; Dehydroepi | 2007 |
30 other studies available for dehydroepiandrosterone and Schizophrenia
| Article | Year |
|---|---|
Cortisol-dehydroepiandrosterone ratios are inversely associated with hippocampal and prefrontal brain volume in schizophrenia.
Topics: Case-Control Studies; Dehydroepiandrosterone; Dorsolateral Prefrontal Cortex; Hippocampus; Humans; H | 2021 |
Gender differences in susceptibility to schizophrenia: Potential implication of neurosteroids.
Topics: Adult; Case-Control Studies; China; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Disease | 2017 |
Pregnenolone-progesterone-allopregnanolone pathway as a potential therapeutic target in first-episode antipsychotic-naïve patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Biomarkers, Pharmacological; Case-Control Studies; Dehydroepiandrostero | 2018 |
Difference of neuro- and immunomodulatory steroids and selected hormone and lipid concentrations between Toxoplasma-free and Toxoplasma-infected but not CMV-free and CMV-infected schizophrenia patients.
Topics: Adult; Antibodies; Blood Glucose; Cholesterol; Cholesterol, LDL; Comorbidity; Cytomegalovirus; Cytom | 2014 |
Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice.
Topics: Adjuvants, Immunologic; Amphetamine; Animals; Apomorphine; Catalepsy; Central Nervous System Stimula | 2014 |
Metabolic syndrome and cortisol/DHEAS ratio in patients with bipolar disorder and schizophrenia.
Topics: Adult; Bipolar Disorder; Blood Pressure; Dehydroepiandrosterone; Female; Humans; Hydrocortisone; Mal | 2014 |
Exploratory investigation of biomarker candidates for suicide in schizophrenia and bipolar disorder.
Topics: Adult; Aged; Autopsy; Biomarkers; Bipolar Disorder; Brain; Case-Control Studies; Chromatography, Hig | 2015 |
DHEA and DHEA-S levels in hospitalized adolescents with first-episode schizophrenia and conduct disorder: a comparison study.
Topics: Adolescent; Conduct Disorder; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Hospit | 2009 |
Serum cortisol and dehydroepiandrosterone-sulfate levels in schizophrenic patients and their first-degree relatives.
Topics: Adult; Dehydroepiandrosterone; Family; Female; Humans; Hydrocortisone; Male; Middle Aged; Schizophre | 2011 |
The influence of DHEA pretreatment on prepulse inhibition and the HPA-axis stress response in rat offspring exposed prenatally to polyriboinosinic-polyribocytidylic-acid (PIC).
Topics: Acoustic Stimulation; Animals; Corticosterone; Dehydroepiandrosterone; Female; Hypothalamo-Hypophyse | 2012 |
Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia.
Topics: Adrenocorticotropic Hormone; Adult; Analysis of Variance; Dehydroepiandrosterone; Humans; Hydrocorti | 2002 |
Movement disorder, memory, psychiatric symptoms and serum DHEA levels in schizophrenic and schizoaffective patients.
Topics: Adult; Aged; Antipsychotic Agents; Chlorpromazine; Dehydroepiandrosterone; Female; Humans; Hydrocort | 2001 |
[REACTIVITY OF SOME LINKS OF THE ENDOCRINE SYSTEM IN VARIOUS FORMS OF SCHIZOPHRENIA. II. REACTIVITY OF THE ENDOCRINE SYSTEM IN PERIODIC FORMS OF SCHIZOPHRENIA].
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenocorticotropic Hormone; Chorion; Chorionic Gonadotr | 1964 |
Use of dehydroisoandrosterone in psychiatric treatment; a preliminary survey.
Topics: Androgens; Biological Assay; Dehydroepiandrosterone; Psychotherapy; Schizophrenia; Steroids | 1952 |
Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Dehydroepiandrosterone; Female; Humans; Hydroc | 2004 |
Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology.
Topics: Adult; Aggression; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Humans; Hydrocort | 2004 |
Plasma dehydroepiandrosterone levels are strongly increased in schizophrenia.
Topics: Adolescent; Adult; Aged; Dehydroepiandrosterone; Diagnostic and Statistical Manual of Mental Disorde | 2005 |
Alterations in DHEA metabolism in schizophrenia: two-month case-control study.
Topics: Adult; Aging; Androstenedione; Antipsychotic Agents; Anxiety; Case-Control Studies; Dehydroepiandros | 2006 |
Cortisol/DHEA ratios in schizophrenia.
Topics: Adrenocorticotropic Hormone; Dehydroepiandrosterone; Gas Chromatography-Mass Spectrometry; Humans; H | 2006 |
State and trait related predictors of serum cortisol to DHEA(S) molar ratios and hormone concentrations in schizophrenia patients.
Topics: Adult; Analysis of Variance; Anxiety; Case-Control Studies; Dehydroepiandrosterone; Dehydroepiandros | 2007 |
Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects.
Topics: Adult; Case-Control Studies; Dehydroepiandrosterone; Female; Humans; Male; Middle Aged; Pregnenolone | 2007 |
Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects.
Topics: Adult; Case-Control Studies; Dehydroepiandrosterone; Female; Humans; Male; Middle Aged; Pregnenolone | 2007 |
Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects.
Topics: Adult; Case-Control Studies; Dehydroepiandrosterone; Female; Humans; Male; Middle Aged; Pregnenolone | 2007 |
Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects.
Topics: Adult; Case-Control Studies; Dehydroepiandrosterone; Female; Humans; Male; Middle Aged; Pregnenolone | 2007 |
Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder.
Topics: Adult; Age Factors; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Biomarkers; Bipol | 2007 |
Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia.
Topics: Adrenomedullin; Adult; Case-Control Studies; Chromatography, High Pressure Liquid; Chronic Disease; | 2007 |
Circulatory neurosteroid levels in smoking and non-smoking chronic schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate | 2007 |
Discrimination between schizophrenic and control subjects by means of plasma dehydroepiandrosterone measurements.
Topics: Adult; Circadian Rhythm; Dehydroepiandrosterone; Humans; Hydrocortisone; Male; Middle Aged; Schizoph | 1981 |
Serum gonadal steroid hormones in young schizophrenic patients.
Topics: Adolescent; Adult; Child; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dopamine; Estradio | 1994 |
Basal plasma dehydroepiandrosterone sulfate level: a possible predictor for response to electroconvulsive therapy in depressed psychotic inpatients.
Topics: Adult; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Depressive Disorder, Major; Electroco | 2000 |
Temporal variations in androgens and stress hormones in control and schizophrenic subjects.
Topics: Androgens; Androstenedione; Dehydroepiandrosterone; Humans; Hydrocortisone; Radioimmunoassay; Schizo | 1979 |
Plasma androgens in male schizophrenics.
Topics: Acute Disease; Adrenal Glands; Adult; Age Factors; Androgens; Androstanes; Androstenes; Chronic Dise | 1972 |
Androgen metabolism in schizophrenics, homosexuals, and normal controls.
Topics: 17-Ketosteroids; Adolescent; Adult; Age Factors; Androgens; Androstanes; Androsterone; Chronic Disea | 1973 |